Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Study of Carbo/Paclitaxel + INCMGA00012/Placebo in Squamous Cell Carcinoma of the Anal Canal

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy

Disease Types: Gastrointestinal

Available at: Roanoke

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy 

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04472429?term=INCMGA00012%2FPlacebo&draw=2&rank=1